{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:07:44Z","timestamp":1790791664848,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Transplant-associated thrombotic microangiopathy (TA-TMA) is a well-recognized complication of hematopoietic cell transplantation (HCT). Diagnosis is challenging and in the absence of a tissue biopsy, TA-TMA is provisionally diagnosed by meeting clinical criteria. In this study, we describe the prevalence, outcomes, and risk factors for meeting 2 different diagnostic criteria for TA-TMA and for increased transplant-related mortality (TRM). In this retrospective study of 307 pediatric HCT patients, records were reviewed for the first 100 days after HCT. Patients who were diagnosed with TA-TMA by a provider during this time were included. In addition, the Cho et al criteria (2010) and Jodele et al (2014) TA-TMA criteria were applied retrospectively. Eight patients (2.6%) were diagnosed with TA-TMA by their provider. However, on retrospective review, 20% and 36% met the Cho and Jodele criteria for TA-TMA, respectively. Overall survival was significantly worse (P\u00a0&amp;lt; .0001) and TRM was significantly higher in patients who met criteria for TA-TMA (MC-TA-TMA) (P\u00a0&amp;lt; .0001). After controlling for comorbid conditions, MC-TA-TMA (hazard ratio [HR], 10.9;\u00a0P\u00a0= .0001) and grade 3\/4 acute graft-versus-host-disease (aGVHD) (HR 3.5;\u00a0P\u00a0= .01) remained independently associated with increased TRM. Among allogeneic HCT recipients, features associated with an increased risk for MC-TA-TMA included \u22652 HCT, concurrent grade 3\/4 aGVHD and concurrent infections. Among patients who MC-TA-TMA, LDH \u22652 times the upper limit of normal (P\u00a0= .001), the need for \u22652 antihypertensive medications (P\u00a0&amp;lt; .0001), and acute kidney injury (P\u00a0= .003) were associated with significantly increased TRM.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001242","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T15:36:32Z","timestamp":1591716992000},"page":"2536-2547","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4565-6399","authenticated-orcid":false,"given":"Michelle","family":"Schoettler","sequence":"first","affiliation":[{"name":"Pediatric Hematopoietic Cellular Therapy, Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA;"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA;"},{"name":"Children\u2019s Healthcare of Atlanta\/Aflac Cancer Center, Atlanta, GA;"},{"name":"Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie E.","family":"Lehmann","sequence":"first","affiliation":[{"name":"Pediatric Hematopoietic Cellular Therapy, Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA;"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Margossian","sequence":"first","affiliation":[{"name":"Pediatric Hematopoietic Cellular Therapy, Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA;"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Lee","sequence":"first","affiliation":[{"name":"Neuroscience Department, Wellesley College, Wellesley, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie S.","family":"Kean","sequence":"first","affiliation":[{"name":"Pediatric Hematopoietic Cellular Therapy, Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA;"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chi","family":"Kao","sequence":"first","affiliation":[{"name":"Hematology\/Oncology, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-9600","authenticated-orcid":false,"given":"Clement","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA;"},{"name":"Hematology\/Oncology, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Duncan","sequence":"first","affiliation":[{"name":"Pediatric Hematopoietic Cellular Therapy, Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA;"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"2","key":"2020060911361471500_B1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.transci.2016.04.007","article-title":"New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"54","author":"Jodele","year":"2016","journal-title":"Transfus Apheresis Sci"},{"issue":"5","key":"2020060911361471500_B2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/bmt.2014.17","article-title":"Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus","volume":"49","author":"Labrador","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2020060911361471500_B3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose carboplatin\/etoposide\/melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2020060911361471500_B4","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.bbmt.2018.12.840","article-title":"Thrombotic microangiopathy following pediatric autologous hematopoietic cell transplantation: a report of significant end-organ dysfunction in eculizumab-treated survivors","volume":"25","author":"Schoettler","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020060911361471500_B5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020060911361471500_B6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"issue":"11","key":"2020060911361471500_B7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/bmt.2008.7","article-title":"Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder","volume":"41","author":"George","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020060911361471500_B8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"2020060911361471500_B9","first-page":"247","article-title":"Bone marrow transplant-associated thrombotic microangiopathy: a case series","volume":"15","author":"Zeigler","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020060911361471500_B10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"issue":"4","key":"2020060911361471500_B11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020060911361471500_B12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2008.419","article-title":"Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy","volume":"44","author":"Inamoto","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020060911361471500_B13","article-title":"Transplant-associated thrombotic microangiopathy (TA-TMA) and consensus based diagnostic and therapeutic recommendations: which TA-TMA patients to treat and when?","volume":"2","author":"Uderzo","year":"2014","journal-title":"J Bone Marrow Res"},{"issue":"8","key":"2020060911361471500_B14","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/bmt.2014.97","article-title":"Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia","volume":"49","author":"Okano","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020060911361471500_B15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13127","article-title":"Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients","volume":"101","author":"Rudoni","year":"2018","journal-title":"Eur J Haematol"},{"issue":"4","key":"2020060911361471500_B16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020060911361471500_B17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JBM.S102235","article-title":"Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment","volume":"7","author":"Rosenthal","year":"2016","journal-title":"J Blood Med"},{"issue":"8","key":"2020060911361471500_B18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"issue":"11","key":"2020060911361471500_B19","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.bbmt.2018.05.010","article-title":"Impact of thrombotic microangiopathy on renal outcomes and survival after hematopoietic stem cell transplantation","volume":"24","author":"Postalcioglu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22)","key":"2020060911361471500_B20","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V128.22.2255.2255","article-title":"Eculizumab therapy of adult TA-TMA: a high response rate is associated with a high infection-related mortality","volume":"128","author":"Bohl","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020060911361471500_B21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020060911361471500_B22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in transplant-associated thrombotic microangiopathy","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"2020060911361471500_B23","first-page":"85","article-title":"Acute kidney injury: definition, pathophysiology and clinical phenotypes","volume":"37","author":"Makris","year":"2016","journal-title":"Clin Biochem Rev"},{"issue":"12","key":"2020060911361471500_B24","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020060911361471500_B25","first-page":"667","article-title":"Bias reduction of maximum likelihood estimates","volume":"82","author":"Firth","year":"1995","journal-title":"Biometrika"},{"issue":"7","key":"2020060911361471500_B26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41409-018-0374-3","article-title":"Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT","volume":"54","author":"Moiseev","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020060911361471500_B27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1473-0502(02)00020-4","article-title":"Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver","volume":"27","author":"Daly","year":"2002","journal-title":"Transfus Apheresis Sci"},{"issue":"3","key":"2020060911361471500_B28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.seminhematol.2018.04.003","article-title":"Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies","volume":"55","author":"Jodele","year":"2018","journal-title":"Semin Hematol"},{"issue":"2","key":"2020060911361471500_B29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020060911361471500_B30","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1702648","article-title":"Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation","volume":"26","author":"Uderzo","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020060911361471500_B31","doi-asserted-by":"crossref","first-page":"e13381","DOI":"10.1111\/petr.13381","article-title":"Severe, persistent neurotoxicity after transplant associated thrombotic microangiopathy (TA-TMA) in a pediatric patient despite treatment with eculizimab","volume":"23","author":"Schoettler","year":"2019","journal-title":"Pediatr Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2536\/1744261\/advancesadv2019001242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2536\/1744261\/advancesadv2019001242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T15:37:07Z","timestamp":1591717027000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/11\/2536\/460731\/Risk-factors-for-transplantassociated-thrombotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001242","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]}}}